Francesco De Rubertis

Francesco is a co-founder and Partner at Medicxi. Prior to Medicxi, Francesco was a Partner at Index Ventures for 19 years, having joined the firm in 1997 to launch its life sciences practice. Under his leadership, the asset-centric approach to life sciences investing was conceived and implemented. Francesco currently serves on the boards of a number of portfolio companies, including Rivus Pharmaceuticals, Levicept, Alys Pharmaceuticals, Aldena Therapeutics, TOAD Oncology, D3 Bio and Ottimo Pharma.

Francesco’s prior investments include Centessa Pharmaceuticals (acquired by Eli Lilly), CellZome (acquired by GlaxoSmithKline), GenMab (Copenhagen:GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Vaxcyte (NASDAQ:PCVX), Molecular Partners (SIX:MOLN), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix), Profibrix (acquired by The Medicines Company), Versartis (NASDAQ:VSAR) and Kaerus Biosciences (acquired by Servier).

Francesco received a BA in Genetics and Microbiology from the University of Pavia and a PhD Molecular Biology from the University of Geneva. He conducted postdoctoral research at the Whitehead Institute at MIT and is a CFA Charterholder.